Regulation of genes of the circadian clock in human colon cancer: Reduced period-1 and dihydropyrimidine dehydrogenase transcription correlates in high-grade tumors

Cancer Research

Volumn 67, Issue 16, 2007, Pages 7917-7922

  Krugluger, Walter ^a,c   Brandstaetter, Anita ^a   Kállay, Enikö ^b   Schueller, Johann ^a   Krexner, Elisabeth ^a   Kriwanek, Stefan ^a   Bonner, Elisabeth ^a   Cross, Heide S ^b  

^a Rudolfstiftung   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; PER1 PROTEIN; PER2 PROTEIN; TRANSCRIPTION FACTOR CLOCK;

ARTICLE; CANCER STAGING; CLINICAL ARTICLE; COLON CANCER; CONTROLLED STUDY; FEMALE; GENE CONTROL; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR GROWTH;

CIRCADIAN RHYTHM; COLONIC NEOPLASMS; DIHYDROURACIL DEHYDROGENASE (NADP); EYE PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC;

EID: 34548049941     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-0133     Document Type: Article

References (50)

1. Tan BR, McLeod HL. Pharmacogenetic influences on treatment response and toxicity in colorectal cancer. Semin Oncol 2005;32:13-9.
2. Van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 2004;40:939-50.
3. Ezzeldin H, Diasio R. Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. Clin Colorectal Cancer 2004;4:181-9.
4. Diaz R, Segura A, Aparizio J, Calderero V, Guerrero A, Pellin L. Lethal toxicity after 5-fluorouracil chemotherapy and its possible relationship to dihydropyrimidine dehydrogenase deficiency: a case report and review of the literature. J Chemother 2004;16:599-603.
5. Naguib FN, Kouni MH, Cha S. Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 1985;45:5405-12.
6. Tanaka-Nozaki M, Onda M, Tanaka N, Kato S. Variations in 5-fluorouracil concentrations of colorectal tissues as compared with dihydropyrimidine dehydrogenase (DPD) enzyme activities and DPD messenger RNA levels. Clin Cancer Res 2001;7:2783-7.
7. Johnston SJ, Ridge SA, Cassidy J, McLeod HL. Regulation of dihydropyrimidine dehydrogenase in colorectal cancer. Clin Cancer Res 1999;5:2566-70.
8. Okumura K, Shiomi H, Mekata E, et al. Correlation between chemosensitivity and mRNA expression level of 5-fluorouracil-related metabolic enzymes during liver metastasis of colorectal cancer. Oncol Rep 2006;15:875-82.
9. Vallbohmer D, Kuramochi H, Shimizu D, et al. Molecular factors of 5-fluorouracil metabolism in colorectal cancer: analysis of primary tumor and lymph node metastasis. Int J Oncol 2006;28:527-33.
10. Salonga D, Danenberg KD, Johnson M, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000;6:1322-7.
11. Hotta T, Takifuji K, Taniguchi K, et al. The relationship between survival and the expression of dihydropyrimidine dehydrogenase in patients with colorectal cancer. Oncol Rep 2006;16:177-82.
12. Kornmann M, Schwabe W, Sander S, et al. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin Cancer Res 2003;9:4116-24.
13. Porsin B, Formento JL, Filipski E, et al. Dihydropyrimidine dehydrogenase circadian rhythm in mouse liver: comparison between enzyme activity and gene expression. Eur J Cancer 2003;39:822-8.
14. Raida M, Kliche KO, Schwabe W, et al. Circadian variation of dihydropyrimidine dehydrogenase mRNA expression in leukocytes and serum cortisol levels in patients with advanced gastrointestinal carcinomas compared to healthy controls. J Cancer Res Clin Oncol 2001;128:96-102.
15. Harris BE, Song R, Soong SJ, Diasio RB. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990;50:197-201.
16. Barrat-Petit MA, Naulin-Ifi C, Mahler P, Milano G. Dihydropyrimidine dehydrogenase (DPD): rhythm and consequences. Pathol Biol Paris 2005;53:261-4.
17. Ripperger JA, Schibler U. Circadian regulation of gene expression in animals. Curr Opin Cell Biol 2001;13:357-62.
18. Zhang J, Dong X, Fujimoto Y, Okamura H. Molecular signals of mammalian circadian clock. Kobe J Med Sci 2004;50:101-9.
19. Damiola F, Minh N, Prenitner N, Kornmann B, Fleury-Olela F, Schibler U. Restricted feeding uncouples circadian oscillators in peripheral tissues from the central pacemaker in the suprachismatic nucleus. Genes Dev 2000;14:2950-61.
20. Schibler U, Sassone-Corsi P. A web of circadian pacemakers. Cell 2002;111:919-22.
21. Davidson AJ, Poole AS, Yamazaki S, Menaker M. Is the food-entrainable circadian oscillator in the digestive system? Genes Brain Behav 2003;2:32-9.
22. Bjarnason GA, Jordan RCK, Wood PA, et al. Circadian expression of clock genes in human oral mucosa and skin. Am J Pathol 2001;158:1793-801.
23. Pardini L, Kaeffer B, Trubuil A, Bourreille A, Galmiche JP. Human intestinal circadian clock: expression of clock genes in colonocytes lining the crypt. Chronobiol Int 2005;22:951-61.
24. ABI prism 7700 sequence detection system: Relative quantitation of gene expression. Bulletin 2, PE Applied Biosystems 2001;1-36.
25. Albrecht U. Functional genomics of sleep and circadian rhythm. Invited review: regulation of mammalian circadian clock genes. J Appl Physiol 2002;92:1348-55.
26. Kondratov RV, Shamanna RK, Kondratova AA, Gorbacheva VY, Antoch MP. Dual role of the CLOCK/ BMAL1 circadian complex in transcriptional regulation. FASEB J 2006;20:530-2.
27. Okamura H. Circadian and seasonal rhythms. Integration of mammalian circadian clock signals: from molecule to behavior. J Endocrinol 2003;177:3-6.
28. Stephan FK, Swann JM, Sisk CL. Anticipation of 24-hr feeding schedules in rats with lesions of the suprachiasmatic nucleus. Behav Neural Biol 1979;25:346-63.
29. Stephan FK. Food entrainable oscillators in mammals. In: Takahashi J, Turek FW, Moore RY, editors. Handbook of behavioral neurobiology 12: Circadian clocks. New York: Plenum Publishers; 2001. pp. 223-41.
30. Mieda M, Williams SC, Richardson JA, Tanaka K, Yanagisawa M. The dorsomedial hypothalamic nucleus as a putative food-entrainable circadian pacemaker. Proc Natl Acad Sci U S A 2006;103:12150-5.
31. Garufi GA, Bjarnason S, Giacchetti P, et al. Independent prognostic value of the rest/activity circadian rhythm on overall survival (OS) in patients (pts) with metastatic colorectal cancer (MCC) receiving first line chemotherapy with 5-fluorouracil, leucovorin and oxaliplatin: a companion study to EORTC 05963. J Clin Oncol 2005 American Society of Clinical Oncology Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II ( June 1 Supplement), 2005:3553.
32. Mormont MC, Waterhouse J, Bleuzen P, et al. Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin Cancer Res 2000;6:3038-45.
33. Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst 2000;21;92:994-1000.
34. Filipski E, King VM, Li X, et al. Host circadian clock as a control point in tumor progression. J Natl Cancer Inst 2002;94:690-7.
35. Filipski E, Li XM, Levi F. Disruption of circadian coordination and malignant growth.. Cancer Causes Control 2006;17:509-14.
36. Shih MC, Yeh KT, Tang KP, Chen JC, Chang JG. Promoter methylation in circadian genes of endometrial cancers detected by methylation-specific PCR. Mol Carcinog 2006;45:732-40.
37. Petit E, Milano G, Levi F, Thyss A, Bailleul F, Schneider M. Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients. Cancer Res 1988;48:1676-9.
38. Grem JL, Yee LK, Venzon DJ, Takimoto CH, Allegra CJ. Inter- and intraindividual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells. Cancer Chemother Pharmacol 1997;40:117-25.
39. Silberstein GB, Van Horn K, Hrah-Robinson E, Compton J. Estrogen-triggered delays in mammary gland gene expression during the estrous cycle: evidence for a novel timing system. J Endocrinol 2006;190:225-39.
40. Wada-Hiraike O, Imamov O, Hiraike H, et al. Role of estrogen receptor β in colonic epithelium. Proc Natl Acad Sci U S A 2006;103:2959-64.
41. Nakamura TJ, Moriya T, Inoue S, et al. Estrogen differentially regulates expression of Per1 and Per2 genes between central and peripheral clocks and between reproductive and nonreproductive tissues in female rats. J Neurosci Res 2005;82:622-30.
42. Numano R, Yamazaki S, Umeda N, et al. Constitutive expression of the Period1 gene impairs behavioral and molecular circadian rhythms. Proc Natl Acad Sci U S A 2006;103:3716-21.
43. Yeh KT, Yang MY, Liu TC, et al. Abnormal expression of period 1 (PER1) in endometrial carcinoma. J Pathol 2005;206:111-20.
44. Chen ST, Choo KB, Hou MF, Yeh KT, Kuo SJ, Chang JG. Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis 2005;26:1241-6.
45. Giachetti S, Bjarnason G, Garufi C, et al. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol 2006;24:3562-9.
46. Lassmann S, Henning M, Rosenberg R, et al. Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors - correlation to tumor histopathology and clinical follow-up. Int J Colorectal Dis 2006;21:238-47.
47. Ichikawa W, Uetake H, Shirota Y, et al. Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Clin Cancer Res 2003;9:786-91.
48. Ciaparrone M, Quirino M, Schinzari G, et al. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil. Oncology 2006;70:366-77.
49. Wood PA, Du-Quiton J, You S, Hrushesky WJ. Circadian clock coordinates cancer cell cycle progression, thymidylate synthase, and 5-fluorouracil therapeutic index. Mol Cancer Ther 2006;5:2023-33.
50. Gery S, Komatsu N, Baldjyan L, Yu A, Koo D, Koeffler HP. The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol Cell 2006;22:375-82.